Mölnlycke and Ondine join forces against HAIs

Gothenburg, Sweden. 19 November 2024. The Cebu Comprehensive Cleft Care Center of Excellence is now officially inaugurated. This milestone is a result of the longstanding partnership between Mölnlycke and Operation Smile – a global non-profit charity organisation. The centre will bring comprehensive care to people born with a cleft lip or palette (CLP) in the region and is expected to serve 10,000 patients in the first three years of its operations. The incidence of babies born with cleft lip and cleft palate is higher in South-East Asia than in other regions globally. The new clinic will offer life-changing surgeries and comprehensive cleft care to patients in the region where access to healthcare services is difficult. “The support from Mölnlycke in establishing the centre is grounded in our commitment to ensure equitable access to healthcare for all and the vision we have for achieving sustainable healthcare. A part of this vision is making the centre self-sufficient, and that includes raising the level of knowledge of the local healthcare professionals in the areas where Mölnlycke can offer expertise”, comments Eric de Kesel, COO & EVP Sustainability, Mölnlycke. “Cleft patients continue to be stigmatised and we are delighted to be able to contribute to changing their lives and fully including them in society,” he adds. “This clinic is a milestone for us, but also for cleft care globally, as it is also a training hub. In a rather lengthy construction project, our partner Mölnlycke has supported us financially while, in parallel with the construction, we have jointly created and rolled out a training programme with innovative methods and solutions,” says Emiliano Romano, Executive Director, Operation Smile Philippines. “Together with some of our volunteers, clinical specialists from Mölnlycke are training the local healthcare professionals in areas such as infection prevention.” The Cebu Comprehensive Cleft Care Center of Excellence is located at the Cebu City Medical Center (CCMC) hospital, in the Philippines. It is a 2,000 m2 state-of-the-art facility providing an optimal environment for delivering comprehensive CLP services, including speech therapy, dental and psychosocial care - in addition to the areas supporting the surgical flow, in alignment with the vision of surgical care that Mölnlycke and Operation Smile share. It is also fully manned by the local healthcare workers. -Ends- For more information, please contact: [Contact card] Sofia Lindqvist   About Operation Smile Operation Smile is a leading global nonprofit bridging the gap in access to essential surgeries and health care, starting with cleft surgery and comprehensive care. We provide medical expertise, training, mentorship, research and care through our dedicated staff and volunteers around the world, working alongside local governments, nonprofits, and health systems, and supported by our generous donors and corporate partners. Visit Operation Smile for more information.

Today, Mölnlycke Health Care, a world leading MedTech company, specialising in wound care and wound management announce a research collaboration with Transdiagen (TDG), a precision medicine company developing drugs and diagnostics for chronic wound healing and tissue regeneration. The collaboration aims to use TDG’s novel wound gene signatures to further explore Mölnlycke products. Emma Wright, EVP Chief Medical Officer, Mölnlycke commented, “We are excited by our research collaboration with TDG allowing us to be at the forefront of advanced understanding of chronic wounds. This opens up a wealth of opportunities for future innovation in the under resourced and under prioritised area of wound care.” James Harding, CEO, Transdiagen added “We are thrilled to be working with Mölnlycke on this R&D programme. This collaboration will allow Mölnlycke access to TDG’s novel models to generate functional insights regarding the mode of action of innovative and biological wound treatment solutions. We believe this marks a new chapter in the approach to data driven, evidence-based product development for the treatment of complex wounds.” The collaboration will be initiated shortly. For more information, please contact: Jennifer Doak contact card About Mölnlycke Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com About Transdiagen Transdiagen (TDG) is a precision medicine company developing drugs and diagnostics for chronic wound healing and tissue regeneration. TDG is driven by the molecular understanding and clinical outcome of chronic wounds and to delivering the right treatment, to the right patient, at the right time. TDG has developed novel Ex Vivo models built on clinically validated mRNA biomarkers linking clinical data and patient outcomes. This is the most advanced disease understanding platform for chronic wounds, and powers the creation of novel diagnostics and drugs. The TDG development models and molecular insights translate laboratory data to clinical outcomes, transforming the development lifecycle of novel interventions directing efficacy, product development, disease, and patient selection. TDG is headquartered in the UK. www.transdiagen.com  

Granudacyn® is a range of solution and gel products intended for use in the cleansing, irrigation and moistening of various wound types. The high quality and composition of Granudacyn ensures biocompatibility, allowing it to be effectively used on a broad range of tissues in acute and chronic wounds, as well as burns. Mölnlycke and P.G.F. have partnered together for more than five years on the manufacturing and distribution of Granudacyn, with Mölnlycke currently distributing Granudacyn in over 50 countries worldwide. “The acquisition of P.G.F. will allow Mölnlycke to expand our Granudacyn business and further develop our growing wound care portfolio. Granudacyn effectively cleanses wounds, which supports healing, ultimately helping to ease the burden of wounds” says Zlatko Rihter, CEO of Mölnlycke Health Care. “I’m excited for our P.G.F. employees to become part of the Mölnlycke team and to expand the reach of Granudacyn to patients most in need. In partnering with P.G.F., Mölnlycke has demonstrated its commitment to helping patients heal their wounds, improving their quality of life” says Peter Fritz, P.G.F. founder. For more information, please contact:   Jennifer Doak contact card About Mölnlycke Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com About P.G.F. Industry Solutions P.G.F. Industry Solutions was founded in 2005 by Peter Fritz to develop and produce ecologically compatible hypochlorous acid based products to protect the user and their environment. The company is founded on more than 30 years of experience in research, development, production, and worldwide distribution of medical and measurement products. P.G.F. employs approximately 25 employees and is headquartered in Elixhausen, Austria. For more information visit www.veriforte.com 

Mölnlycke Health Care partners with Ondine for Steriwave distribution collaboration in the key markets of the UK, Europe and the Middle East.  Gothenburg, Sweden 23 September 2024. Mölnlycke® Health Care, a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures and Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, are pleased to announce a strategic partnership to bring Ondine’s Steriwave® nasal decolonisation technology to the United Kingdom, EU and Middle East markets.  This collaboration marks a significant milestone in the fight against healthcare-associated infections (HAIs) and the growing threat of antimicrobial resistance (AMR), as Steriwave safely reduces hospital infections without generating AMR. Steriwave, a non-antibiotic, light-activated nasal decolonisation therapy, has been clinically proven[1[2][3][4][5] to reduce harmful pathogens in the nasal passages, a common source of HAIs and cause of higher rates of mortality, length of stay and readmissions. Mölnlycke’s established distribution networks, strong brand and market presence in over 100 countries make it an ideal partner to accelerate the adoption of Steriwave. The first market focus, starting later this year, is the pivotal UK market where Steriwave is already deployed in a number of National Health Service (NHS) Trusts, including, Mid Yorkshire Teaching NHS Trust and Leeds Teaching Hospital NHS Trust. Steriwave is also listed with NHS Supply Chain, a national body that manages the sourcing, delivery and supply of healthcare products to the NHS and healthcare organisations in England and Wales. The UK, with a total addressable market of over 3 million major surgeries annually[6] and over 200,000 annual intensive care unit (ICU) admissions,[7] has significant global influence in setting best practice for patient care. Mölnlycke will incorporate Steriwave as a key product in its infection control portfolio, enhancing its product offerings with a focus on preventing HAIs and reducing AMR. Distribution will commence in the UK in Q4 2024, followed by expansion into the EU and Middle East regions in 2025, leveraging Mölnlycke’s extensive market presence to ultimately broaden the impact of this innovative technology on a global scale. Mölnlycke will spearhead sales and marketing efforts across the UK, EU, and Middle East. Lina Karlsson, Executive Vice President Antiseptics, Mölnlycke, stated: “Mölnlycke’s purpose is to revolutionise care for people and planet. In the Antiseptics business area, we do this by making patient skin decolonisation manageable and motivational. We believe that Steriwave can improve the lives of millions of people, fitting perfectly with our purpose and mission. The ability to rapidly eliminate multiple drug-resistant pathogens without generating antimicrobial resistance is key to our sustainability initiative, and complements our Hibiwash® brand skin prep line, enabling us to provide comprehensive ‘nose-to-toes’ decolonisation prior to surgery. Universal decolonisation is now a well-accepted practice to improve surgical outcomes and produce significant cost savings to healthcare systems.” Carolyn Cross, CEO of Ondine Biomedical, commented: “We are excited to be partnering with Mölnlycke Health Care, whose global reach, corporate vision and commitment to sustainable healthcare aligns perfectly with our own core values, purpose and mission. The Mölnlycke collaboration represents a transformative step towards our ambitious plans to combat HAIs and antimicrobial resistance globally.  We look forward to working with Mölnlycke in these initial key markets and beyond.” HAIs remain a critical challenge across the world, consuming approximately 6% of European public sector budgets[8] and resulting in significant costs, avoidable deaths, and human suffering. Post-surgical infections, in particular, extend recovery times and often require prolonged antibiotic treatment, something the UK government is actively seeking to reduce as part of its 5-year action plan for antimicrobial resistance, published in May 2024[9]. Nasal decolonisation is recommended in the 2016 WHO Global guidelines for the prevention of surgical site infections[10], and the Society for Healthcare Epidemiology of America (SHEA) guidelines, published in May 2023, recommend nasal decolonisation for major surgical procedures[11]. Steriwave uses a patented light-activated agent to rapidly eliminate infection-causing pathogens in a single, 5-minute treatment. The process works so rapidly that pathogens do not have the opportunity to develop resistance,[12] making it an effective alternative to antibiotics. Hospitals using Steriwave have reported high levels of staff and patient compliance. Steriwave has also been proven to be highly effective against drug-resistant pathogens. A 2023 study showed that Steriwave is highly effective (>99.99% kills in 20 seconds) against both moderately drug-resistant (MDR) and extensively drug-resistant (XDR) pathogens.[13] -Ends- About Ondine Biomedical Inc. Ondine Biomedical Inc. is a Canadian life sciences company and leader innovating light-activated antimicrobial therapies (also known as 'photodisinfection'). In addition to Steriwave, Ondine has a pipeline of products, based on its proprietary photodisinfection technology, in various stages of development. Ondine's nasal photodisinfection system has a CE mark in Europe and the UK and is approved in Canada and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications. About Steriwave® Ondine’s Steriwave nasal photodisinfection system is a patented technology using a proprietary light-activated antimicrobial (photosensitiser) to destroy bacteria, viruses, and fungi colonising the nose. The photodisinfection treatment is carried out by a trained healthcare professional and is an easy-to-use, painless, two-step process. The photosensitiser is applied to each nostril using a nasal swab, followed by illumination of the area with a specific wavelength of red laser light for less than five minutes. The light activates the photosensitiser, causing an oxidative burst that is lethal to all types of pathogens without causing long-term adverse effects on the nasal microbiome. A key benefit of this approach — unlike antibiotics, which have resistance rates reported as high as 81% — is that pathogens do not develop resistance to the therapy[i]. For more information: Contact card Mathilda Blomsterberg References [1] Bryce E, Wong T, Forrester L, et al. Nasal photodisinfection and chlorhexidine wipes decrease surgical site infections: a historical control study and propensity analysis [published correction appears in J Hosp Infect. 2015 Sep;91(1):93]. J Hosp Infect. 2014;88(2):89-95. (link) [2] Moskven E, Banaszek D, Sayre EC, et al. Effectiveness of prophylactic intranasal photodynamic disinfection therapy and chlorhexidine gluconate body wipes for surgical site infection prophylaxis in adult spine surgery. Can J Surg. 2023;66(6):E550-E560. (link) [3] Ondine Biomedical’s nasal photodisinfection cuts surgical site infections by 66%. Press release 18 April 2023 (link) [4] Pre-op Nasal Decolonization via Photodisinfection: A Pilot Study in Spinal Surgery Procedures at the Ottawa Hospital. Poster presentation at IPAC Canada 2023 National Conference. (link) [5] Street C, Pedigo L, Gibbs A, et al. Antimicrobial photodynamic therapy for the decolonization of methicillin-resistant Staphylococcus aureus from the anterior nares. In: Kessel DH, editor. Photodynamic therapy: back to the future. 12th World Congress of the International Photodynamic Association. Vol. 7380 of Proceedings series. Bellingham (WA): SPIE; 2009. (link) [6] Surgical Procedure Volumes in UK from 2021-2029. Life Science Intelligence; 2023 Jan. Volume 23. [7] Hospital Admitted Patient Care Activity, 2011-22. Secondary Care Analytical Team, NHS Digital. Health and Social Care Information Centre. 22 Sep 2022. (link) [8] OECD/European Union (2020), Health at a Glance: Europe 2020: State of Health in the EU Cycle, OECD Publishing, Paris. (link) [9] UK Government. UK 5-year action plan for antimicrobial resistance 2024 to 2029. London: Department of Health and Social Care; 2024. (link) [10] Surgical Site Infection Prevention: Key facts on decolonization of nasal carriers of Staphylococcus aureus. World Health Organization. (link) [11] Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023;44(5):695-720. (link) [12] Pedigo LA, Gibbs AJ, Scott RJ, et al. Absence of bacterial resistance following repeat exposure to photodynamic therapy. Proc. SPIE 7380, Photodynamic Therapy: Back to the Future, 73803H (2009). (link) [13] Romo-Bernal C, Sabino C, Chavez M, et al. Antimicrobial Photodynamic Therapy Against Extensively Drug-Resistant (XDR) Gram-Negative Isolates with Novel Antibiotic Resistance Factors. Poster presented at: ICPIC2023; 12-15 September 2023; Geneva. (link)

Mölnlycke has been awarded the platinum medal in Ecovadis Sustainability Rating, which places us in the top 1 percent of all companies assessed. EcoVadis is a globally trusted provider of business sustainability ratings with a network of more than 130,000 rated companies. Their rating recognises Mölnlycke’s strengths in environmental impact management, labour & human rights interactions, ethical governance and sustainable supply chain partnerships. Mölnlycke have been utilising feedback from EcoVadis, business partners and customers to drive continual improvement in sustainability each year. The acknowledgement of Mölnlycke’s achievments in these areas motivates us to be bolder and go further, driving positive change both for people and planet.

Gothenburg, Sweden 15 July 2024. Mölnlycke Health Care, a world-leading MedTech company specialising in solutions for wound care and surgical procedures, announced today an investment of US $15m in MediWound Ltd. (Nasdaq: MDWD)(MediWound) through a definitive share purchase agreement in a private investment in public equity (PIPE). MediWound, a global leader in next-generation enzymatic therapeutics focused on non-surgical wound debridement, has a vision to improve the existing standards of care and patient experiences, while reducing costs and unnecessary surgeries. Debridement is a standard of care step to prepare the wound bed for healing and can help in the management of infection. It involves the removal of dead or devitalised tissue from a wound. “We are very excited to make this strategic investment in MediWound. It aligns with our strategy to bring radical innovations into the wound care space and provide alternative solutions to the more traditional debridement options to improve clinical outcomes and patient experience,” said Zlatko Rihter, CEO of Mölnlycke. “This investment will support Mölnlycke’s Wound Care mission to ‘help free patients from the burden of wounds’ and I look forward to this partnership.” Mölnlycke and MediWound have also entered into a collaboration agreement to strengthen their partnership. Under the key terms of this agreement, Mölnlycke is granted specific rights, including having a representative attend meetings of MediWound’s R&D Committee and will also be able to participate in potential strategic partnership discussions and M&A processes under certain circumstances. “We are delighted to have Mölnlycke’s support. This substantial investment will empower us to strengthen our strategic plans, creating significant long-term value for our stakeholders and help to improve standards of care for patients” said Ofer Gonen, CEO of MediWound. For more information, please contact: Jennifer Doak, Global Communications Director Wound Care Email: jennifer.doak@molnlycke.com Phone: +1 678 206 6179 Ellie Hanson, FINN Partners for MediWound Email: ellie.hanson@finnpartners.com Phone : +1 929-588 2008         About Mölnlycke Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com About MediWound MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that improve existing standards of care and patient experiences, while reducing costs and unnecessary surgeries. MediWound first drug, NexoBrid®, is an FDA and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, which can significantly reduce surgical interventions. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline, including the company’s lead drug under development, EscharEx®. EscharEx is a Phase III-ready biologic for the debridement of chronic wounds, offering significant potential advantages over the dominant $360+ million product and an opportunity to expand the market. For more information visit www.mediwound.com and follow the Company on LinkedIn.

How to stay safe and avoid burns Make sure your grill is in a safe location. The grill should be placed well away from the home, deck railings and out from under eaves and overhanging branches. Only grill outside. Keep children and pets away. Keep children and pets at least one meter away from the grill area. Keep your grill clean. Keep your grill clean by removing grease or fat buildup from the grills and in trays below the grill. Let it cool completely. When you are finished grilling, let the coals cool completely before disposing of them in a metal container.

Longstanding partners, Mölnlycke Health Care and Scan Global Logistics (SGL), have entered an agreement for the purchase and deployment of ocean biofuel covering trade lanes from Asia to Europe to further reduce carbon emissions. This decision supports the global MedTech company Mölnlycke's commitment to reducing greenhouse gas (GHG) emissions and reaching Net Zero by 2050. For over 15 years, Scan Global Logistics have had a close global partnership with Mölnlycke, marked by a shared focus on supply chain optimisation and mitigating greenhouse gas (GHG) emissions associated with maritime transportation. In recent years, this collaboration has seen a heightened emphasis on sustainability initiatives, culminating in exploring actions to reduce environmental impact, which resulted in the company now buying ocean biofuel. Eric de Kesel, COO & EVP Sustainability, Mölnlycke, elaborates on this decision: “We are committed to driving our sustainability efforts forward and firmly believe we can reduce emissions while maintaining the quality of our business operations. The partnership with Scan Global Logistics to purchase a significant amount of biofuel for our ocean shipments is important and beneficial from a business, economic, and environmental standpoint, particularly for our Asia-Europe routes.” Striking a balance: Sustainable and economical solutions in logistics Both companies recognise the importance of offering tangible solutions to address climate change-related  concerns, anchoring their collaboration in a mutual commitment to push for positive change. Kim Fischer, Corporate EVP, Global Sales & Corporate Strategic Accounts in Scan Global Logistics, reinforces this commitment: “Mölnlycke is very important to us, and our relationship dates back over a decade. This initiative underlines the dynamic and innovative approach that both companies are investing in a successful business collaboration. Further sustainability initiatives have already been discussed with Mölnlycke, and we value such entrepreneurship, which aligns with our business approach.” Marc Bach Spangsberg Sørensen, Global Head of Program Management at Scan Global Logistics, continues: ”We are dedicated to expanding the portfolio of relevant products offered to our customers in an ever-changing world. Through strategic collaborations, we promote the agenda for alternative fuel types, contributing to the long-term transition to low-emisssion transport solutions.” Central to this collaboration is the ability to provide customers like Mölnlycke with accessible, measurable, and ready-for-use products that facilitate GHG emission reduction. By leveraging biofuel for ocean freight, SGL aim to deliver environmental and economic benefits through cost-effective pricing structures. Partnerhips as drivers for positive change Martin Andersen, Global Head of Sustainability & ESG at Scan Global Logistics, is excited about the collective courage among companies which will support the demand for ocean biofuel and actual emission reductions: ”It is paramount and uplifting to see responsible companies drive their decarbonisation journey. It is a challenge, but we all must contribute and support each other with collaboration across industries and supply chains, which is essential to making progress. The window for meaningful change is closing; now is the time to drive collective courage for a low-carbon future.” In conclusion, this partnership for ocean biofuel represents a positive step towards low-carbon logistics. While navigating the complexities of modern logistics, collaborations like these serve as examples of optimism and pave the way towards a more sustainable future for the industry.  

Today, Mölnlycke Health Care, a world leading MedTech company, announces that its near-term GHG emission reduction targets submitted to the SBTi have been validated and deemed to be compliant with all applicable requirements. Specifically, Mölnlycke has committed to reduce absolute scope 1 and 2 GHG emissions by 50% by 2030, from a 2021 base year, to increase active annual sourcing of renewable electricity from 23% in 2021 to 100% by 2024, and to continue sourcing of 100% renewable electricity through 2030. Furthermore, the company committed to reducing absolute scope 3 GHG emissions from purchased goods and services, fuel and energy related activities, upstream transportation and distribution and waste generated in operations by 20% by 2028, from a 2021 base year. Finally, Mölnlycke committed that 63% of its suppliers by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, will have set science-based targets by 2028. “SBTi validation is a key milestone in our long-term strategy to help decarbonise the healthcare sector” said Zlatko Rihter, Chief Executive Officer, Mölnlycke Health Care. “We are committed to reach Net Zero by 2050 at the latest, and are accelerating the process of minimising both the direct and indirect impact of our operations on the planet.” Mölnlycke stands well poised for reaching the targets through a series of impact initiatives: For scope 1 and scope 2 targets concerning our own manufacturing facilities and headquarters, Mölnlycke’s implementation of a renewable electricity roadmap is well underway and will be achieved through a combination of virtual Power Purchase Agreements, renewable energy certificates (RECs) and investments in higher additionality energy sources, e.g. photovoltaic systems. For scope 3 and the supplier engagement target, Mölnlycke has already initiated activities under the Sustainable Procurement framework aimed at increasing collaboration with suppliers to bring innovation in raw materials and improved transportation routes that are needed to transition to a low-carbon economy. Mölnlycke are ensuring a defined set of suppliers commit to reducing emissions through the SBTi. The official information on Mölnlycke’s commitment can be found here. About SBTi The Science Based Targets Initiative (SBTi) is a global partnership made up of leading climate organisations, including the Carbon Disclosure Project, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). The SBTi defines and promotes best practice in emissions reductions and Net-zero targets in line with science. It provides technical assistance and expert resources to companies that set science-based targets, to ensure their alignment with the Paris Agreement, to limit global warming to 1.5C.

The bond was more than five times oversubscribed with an orderbook of over EUR 2,700M at its peak. There was strong and widespread demand from leading investors in Germany, Austria and Switzerland 32%, UK & Ireland 28%, Nordics 18%, France 12% and Other 10%. Asset Managers represented 87% of investors, followed by Insurance and Pension Funds with 9% and Banks with 4%. The proceeds will be used to finance a Tender Offer of Mölnlycke’s outstanding EUR 500M notes maturing in 2025 as well as for general corporate purposes. The bond further extends the duration of Mölnlycke’s well-spread debt maturity profile. The bond will be listed on the Euro MTF market of the Luxembourg Stock Exchange. BNP Paribas, ING, JP Morgan and SEB acted as joint bookrunners for the transaction.

Mölnlycke intends to issue a new 10-year EUR bond under its Euro Medium Term Note (EMTN) programme. The bond will be listed on the Euro MTF market of the Luxembourg Stock Exchange. At the same time Mölnlycke invites its holders of the outstanding EUR 500m bond due February 2025 note to tender any and all of their notes for purchase by the company. Read the full announcement here.

Since 1977, Phoenix Society has served burn survivors, their loved ones, burn care professionals, researchers and others committed to empowering the burn community to enable transformational healing. With the overarching vision of uniting the voice of the burn community globally to “advance lifelong healing, optimal recovery, and burn prevention”, the Phoenix Society offers programmes, tools, education and events to bring this vision to life. With our wide range of burn care solutions including for example cleansing, gentle wound dressings and scar management, Mölnlycke is uniquely positioned to support Phoenix Society initiatives. Our advanced wound care dressings are enabled by Safetac® technology, a gentle silicone adhesive that reduces pain and minimises skin trauma of burn survivors at dressing change. Mölnlycke also provide information about burn dressings and healing through educational content, clinical evidence, and tips and tricks on how to apply burn care. Inline quote: Anders Andersson   The power of partnership The partnership between Phoenix Society and Mölnlycke brings together two organisations driven by a mission to make survivors’ healing easier and their lives fuller by reaching survivors earlier, minimising the impact of burns and giving survivors the solutions, resources and community needed to facilitate recovery and support.

The Tamer Mölnlycke Care joint venture was initiated in 2021 with the agreement to develop a customised surgical procedure tray factory in Saudi Arabia, with first production expected in Q4 2024. The increased investment allows for an expansion in the range of Mölnlycke products manufactured and distributed in the country and to the neighbouring region. Adding drapes and gowns, emollient range and selected wound care products to the offering allows more healthcare professionals and patients in the region to benefit from Mölnlycke products and solutions. Zlatko Rihter, CEO, Mölnlycke Health Care comments “To ensure we meet customer demand, geographical expansion is a strategic priority for Mölnlycke Health Care. Increased investment in our existing long-term partnership with Tamer Group will importantly enable healthcare professionals and patients in Saudi Arabia access to our quality products and solutions helping to improve outcomes, and is a step closer to realising the potential of this rapidly growing healthcare market.” Speaking on behalf of Tamer Group, Chairman Ayman Tamer adds “This investment is key to enabling future growth in the region as outlined in the Saudi Vision 2030 - supporting the regional healthcare ecosystem, including exporting goods to the Middle East and Africa region, whilst developing local skills and expertise.” Mahmoud Wagih, CEO, Tamer Mölnlycke Care comments “I am delighted to lead this business where Mölnlycke and Tamer will build a strong, long-term successful joint venture, bringing superior health care solutions to our region.” The Tamer Mölnlycke Care joint venture is a long-term agreement between two organisations who have been working in partnership over the past decade; and are committed to meeting customer demand in the evolving healthcare landscape of Saudi Arabia and the wider region. For more information, please contact:  Liz Neal Director of Communications Email: liz.neal@molnlycke.com Phone: +44 7787432560 About Mölnlycke   Mölnlycke is a world-leading medical products and solutions company that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. The core business is within the four Business Areas Wound Care, Operating Room Solutions (ORS), Gloves and Antiseptics.  Mölnlycke employs around 8,700 people. The headquarters are in Gothenburg, Sweden, and the company operates in more than 100 countries worldwide. Mölnlycke is owned by Patricia Industries AB, which is part of Investor AB, an engaged owner of high-quality, global companies founded by the Wallenberg family in 1916. www.molnlycke.com   

Gothenburg 12 April 2024: Mölnlycke, a world leading MedTech company specialised in wound care and wound management, announced today it signed an agreement to acquire P.G.F. Industry Solutions GmbH, the Austrian manufacturer of Granudacyn wound cleansing and moisturising solutions. Mölnlycke and P.G.F. have worked together for five years on the manufacturing and distribution of Granudacyn, a range of solution and gel products intended for use in the cleansing, irrigation and moisturisation of various wound types. The high quality and composition of Granudacyn ensures good biocompatibility, allowing it to be effectively used on a broad range of tissues in burns, as well as acute and chronic wounds. Mölnlycke currently distributes Granudacyn in over 50 countries around the world. “With an ageing population in combination with increased chronic wounds, such as diabetic foot ulcers or venous leg ulcers, it is our obligation to help ease the burden of wounds on national healthcare regimes” says Zlatko Rihter, CEO of Mölnlycke Health Care. “The acquisition of P.G.F. and its state-of-the-art manufacturing plant, will allow Mölnlycke to aggressively expand our Granudacyn business to improve the lives of even more patients.” “I’m excited for P.G.F. to become part of Mölnlycke and for the team to continue to manufacture products that support Mölnlycke’s Wound Care mission to help free patients from the burden of wounds” says Peter Fritz, P.G.F. founder and CEO, who will continue to lead this team and manufacturing process from P.G.F.’s Austria headquarters. Closure is expected after certain milestones are reached and will be communicated separately. For more information, please contact: Jennifer Doak Global Communications Director Wound Care Email: jennifer.doak@molnlycke.com Phone: +1 678 206 6179 About Mölnlycke® Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com About P.G.F. Industry Solutions P.G.F. Industry Solutions was founded in 2005 by Peter Fritz to develop and produce ecologically compatible hypochlorous acid based products to protect the user and their environment. The company is founded on more than 30 years of experience in research, development, production, and worldwide distribution of medical and measurement products. P.G.F. employs approximately 25 employees and is headquartered in Elixhausen, Austria. www.veriforte.com.

Performance highlights Mölnlycke reported strong growth in 2023, with net sales reaching EUR 1,924 million, an 8% increase in constant currency rates. The EBITDA grew by 14% to EUR 545 million, reflecting substantial organic growth and market share gains across most markets. Sustainability achievements We made significant strides in operationalising our sustainability roadmap 2030. Mölnlycke’s near-term greenhouse gas emission reduction targets were validated by the Science Based Targets initiative. Noteworthy progress was made in our journey towards 100% fossil-free electricity by the end of 2024, with 61% fossil-free electricity share in 2023. We also achieved a 20% reduction in overall absolute greenhouse gas emissions across the entire value chain compared to the 2021 baseline. Finally, we expanded the scope of Life Cycle Assessment to cover 30% of our portfolio in terms of net sales. Zlatko annual report news quote   Innovation and quality highlights To enhance surgical performance, Mölnlycke introduced hand scanning technology using artificial intelligence and machine learning for optimal glove fit, launched Mepilex® Up in the US, upgraded the Mepilex® Border Post-Op product family globally and registered Hibiwash®, - the new colour- and fragrance-free Hibi formula. We also successfully completed the transition to Medical Device Regulation (MDR), one of the first MedTech companies to do so. Strategic investments Mölnlycke secured long-term financing through a EUR 400 million Eurobond and a EUR 350 million Revolving Credit Facility. We also decided to invest EUR 60 million to increase production capacity, including a new Mepilex Border Flex production line and a new Ethylene Oxide sterilisation unit in Finland.

The benchmarking procedure Mölnlycke are in the second year of working with EcoVadis as an independent and credible organisation to benchmark strengths and improvement opportunities. The rating process required extensive amounts of data and documentation, and therefore teamwork between global sustainability, legal and compliance, information technology, procurement excellence, and people experience teams. Our submission was assessed over a four week period. As a continuation from the previous assessment, results and feedback will be used to prioritise improvement plans. The result A gold medal is awarded to the all top 5%, and our score puts us into the top 3% of all organisations from all industries worldwide. Particularly recognized during the submission were Mölnlycke's commitment to Science Based Targets and measurable improvements in emissions, ​the strength of Mölnlycke procedures relating to human rights, ​demonstrable progress in gender equality, ​and the availability of the Ethics Hotline to all Mölnlycke's stakeholders The results certificate is available to download for verification below, EcoVadis will also provide a detailed validated scorecard to users of their platform.

The facility is backed by a group of seven leading global and regional banks, well diversified to match Mölnlycke’s geographical footprint. The banks are BNP, Danske Bank, HSBC, ING, JP Morgan, Nordea and SEB as mandated lead arrangers. SEB acted as the coordinator, documentation agent and facility agent for the transaction. For more information, please contact:  Liz Neal Director of Communications Email: liz.neal@molnlycke.com Phone: +44 7787432560 About Mölnlycke   Mölnlycke is a world-leading medical products and solutions company that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. The core business is within the four Business Areas Wound Care, Operating Room Solutions (ORS), Gloves and Antiseptics.  Mölnlycke employs around 8,700 people. The headquarters are in Gothenburg, Sweden, and the company operates in more than 100 countries worldwide. Mölnlycke is owned by Patricia Industries AB, which is part of Investor AB, an engaged owner of high-quality, global companies founded by the Wallenberg family in 1916. www.molnlycke.com 

Being born with a cleft lip or palate is more than just a cosmetic problem. Many children have issues eating or speaking. They can grow up isolated, unable to socialise and deprived of opportunities. The Philippines has one of the highest incidences of cleft palate and cleft lip in the world. A simple surgical procedure can correct cleft problems. But access to healthcare is low in the country, particularly for people living outside the two main islands, and there is a need to enhance the specialist cleft care skills of healthcare professionals. 10,000 surgeries in three years The centre, which is planned to open in Q4 2021, will serve the 27 million people who live on Cebu or one of the 150+ surrounding islands. In its first three years, Operation Smile and Mölnlycke estimate that the centre will support up to 10,000 surgeries, via a hub and spokes model in the community. More than 26,000 patients will receive consultations and 1,800 community health workers will be trained – alongside 400 Operation Smile volunteers and hospital staff. Supporting with funds, products and expertise Mölnlycke has committed to an initial three-year partnership agreement to support the centre at Cebu. In addition to funds, the company will donate products, train healthcare professionals in infection prevention and provide logistics support. As expertise within Cebu and the surrounding area grows, the ambition is for the centre to become less reliant on direct support and more self-sufficient. Zlatko cleft centre Quote Follow #Cebu10000 #Cebu10000 is the first time Mölnlycke has supported healthcare infrastructure and marks a significant step-change in the company’s relationship with its global charity partner Operation Smile. Since 2004, when Mölnlycke began its support of Operation Smile, the company has donated funds, volunteer time and more than 1.5 million pairs of Biogel® surgical gloves to support cleft procedures. A model of cleft care Bill Magee Cleft centre Quote   Press contact Liz Neal Director of Communications Email: liz.neal@molnlycke.com Phone: +44 7787432560   About Mölnlycke Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com